Trial · NCT03222609
Adverse events1,012
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
41 to 60 of 1,012
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | VISION BLURRED | Eye disorders | Navitoclax + Ruxolitinib (Cohort 1a) | 1 | 34 | 1 |
| other | VISION BLURRED | Eye disorders | Navitoclax + Ruxolitinib (Cohort 1b) | 1 | 91 | 1 |
| other | VISION BLURRED | Eye disorders | Navitoclax (Cohort 2) | 0 | 34 | 0 |
| other | VISION BLURRED | Eye disorders | Navitoclax + Ruxolitinib (Cohort 3) | 2 | 32 | 2 |
| other | VITREOUS FLOATERS | Eye disorders | Navitoclax + Ruxolitinib (Cohort 1a) | 2 | 34 | 2 |
| other | VITREOUS FLOATERS | Eye disorders | Navitoclax + Ruxolitinib (Cohort 1b) | 0 | 91 | 0 |
| other | VITREOUS FLOATERS | Eye disorders | Navitoclax (Cohort 2) | 0 | 34 | 0 |
| other | VITREOUS FLOATERS | Eye disorders | Navitoclax + Ruxolitinib (Cohort 3) | 1 | 32 | 1 |
| other | ABDOMINAL DISCOMFORT | Gastrointestinal disorders | Navitoclax + Ruxolitinib (Cohort 1a) | 3 | 34 | 3 |
| other | ABDOMINAL DISCOMFORT | Gastrointestinal disorders | Navitoclax + Ruxolitinib (Cohort 1b) | 5 | 91 | 6 |
| other | ABDOMINAL DISCOMFORT | Gastrointestinal disorders | Navitoclax (Cohort 2) | 1 | 34 | 1 |
| other | ABDOMINAL DISCOMFORT | Gastrointestinal disorders | Navitoclax + Ruxolitinib (Cohort 3) | 4 | 32 | 5 |
| other | ABDOMINAL DISTENSION | Gastrointestinal disorders | Navitoclax + Ruxolitinib (Cohort 1a) | 5 | 34 | 5 |
| other | ABDOMINAL DISTENSION | Gastrointestinal disorders | Navitoclax + Ruxolitinib (Cohort 1b) | 4 | 91 | 6 |
| other | ABDOMINAL DISTENSION | Gastrointestinal disorders | Navitoclax (Cohort 2) | 5 | 34 | 5 |
| other | ABDOMINAL DISTENSION | Gastrointestinal disorders | Navitoclax + Ruxolitinib (Cohort 3) | 3 | 32 | 4 |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | Navitoclax + Ruxolitinib (Cohort 1a) | 7 | 34 | 8 |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | Navitoclax + Ruxolitinib (Cohort 1b) | 11 | 91 | 16 |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | Navitoclax (Cohort 2) | 5 | 34 | 6 |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | Navitoclax + Ruxolitinib (Cohort 3) | 6 | 32 | 10 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03222609/events?page=3